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Abstract: The in vitro modeling of cardiac development and cardiomyopathies in human induced
pluripotent stem cell (iPSC)-derived cardiomyocytes (CMs) provides opportunities to aid the dis-
covery of genetic, molecular, and developmental changes that are causal to, or influence, cardiomy-
opathies and related diseases. To better understand the functional and disease modeling potential of
iPSC-differentiated CMs and to provide a proof of principle for large, epidemiological-scale disease
gene discovery approaches into cardiomyopathies, well-characterized CMs, generated from validated
iPSCs of 12 individuals who belong to four sibships, and one of whom reported a major adverse
cardiac event (MACE), were analyzed by genome-wide mRNA sequencing. The generated CMs
expressed CM-specific genes and were highly concordant in their total expressed transcriptome
across the 12 samples (correlation coefficient at 95% CI =0.92 ± 0.02). The functional annotation
and enrichment analysis of the 2116 genes that were significantly upregulated in CMs suggest that
generated CMs have a transcriptomic and functional profile of immature atrial-like CMs; however,
the CMs-upregulated transcriptome also showed high overlap and significant enrichment in pri-
mary cardiomyocyte (p-value = 4.36 × 10−9), primary heart tissue (p-value = 1.37 × 10−41) and
cardiomyopathy (p-value = 1.13 × 10−21) associated gene sets. Modeling the effect of MACE in the
generated CMs-upregulated transcriptome identified gene expression phenotypes consistent with the
predisposition of the MACE-affected sibship to arrhythmia, prothrombotic, and atherosclerosis risk.
Keywords: human; induced pluripotent stem cell; cardiomyocytes; cardiomyopathies; genome-wide
mRNA sequencing
1. Introduction
Cardiomyopathies are a heterogeneous group of diseases caused by pathological
alterations in myocardial structure and function and often progress into heart failure (HF)
and death. The myocardial alterations can be either solely or predominantly confined
to the heart, in which they are generally classified as primary cardiomyopathies or as
part of more generalized systemic (multiorgan) disorders that are classified as secondary
cardiomyopathies. Both primary and secondary cardiomyopathies may result from genetic
predisposition and/or acquired non-genetic factors including exposure to environmental
toxins, chemotherapeutic drugs, or infectious agents [1]. Based on the structural and func-
tional changes that take place at the whole-organ level, cardiomyopathies are classically
divided into (i) dilated cardiomyopathy (DCM), defined as the dilatation of the left or both
ventricles as a consequence of impaired myocardial contractility in the absence of abnormal
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overload and/or ischemic heart disease [2]; (ii) hypertrophic cardiomyopathy (HCM),
characterized by inappropriate myocardial hypertrophy that develops in the absence of
pressure overload or infiltration [3]; (iii) arrhythmogenic cardiomyopathy (AC), charac-
terized by progressive fibrofatty replacement of the ventricular myocardium leading to
arrhythmia, HF, and sudden cardiac death [4]; and (iv) restrictive cardiomyopathy (RCM),
characterized by impaired ventricular filling and diastolic function with relatively nor-
mal ventricular wall thickness and systolic function [5]. This traditional classification has
continuing relevance for clinical diagnosis and management; however, there is extensive
overlap between these phenotypes. For example, HCM or AC may progress into a dilated
ventricle with systolic dysfunction and hence the appearance of DCM [3,6]. Furthermore,
DCM encompasses a wide range of genetic and acquired disorders having a greater or
lesser impact in different patients and over the course of a patient’s life [7,8]. For example,
early DCM stages may present intermediate phenotypes that do not meet the classical
definition of the disease. Therefore, cellular and molecular phenotypes, and diagnostic
criteria that are more precise and robust, are needed for early detection and interventions
in cardiomyopathies.
The monogenic form of inherited cardiomyopathies represents a small proportion
of all HF cases; however, this varies significantly by age and population studied [9,10].
Susceptibility to HF was identified as a complex heritable trait in the Framingham Off-
spring cohort, even after adjusting for comorbidities like myocardial infarction, diabetes
mellitus, and hypertension [11]. Furthermore, due to the heterogeneous nature of the
disease phenotype and disease penetrance, precise data showing prevalence of different
cardiomyopathies in the general population are lacking. For example, overall prevalence of
idiopathic DCM is estimated at around 1 case per 2500 individuals; however, a frequency
ten times higher than this estimate was reported in a previous publication [7], suggesting a
large proportion of this debilitating disease, and its predisposition goes undetected or is
detected at a very late stage.
Early breakthroughs with in vitro modeling of cardiac development and cardiomy-
opathies in human embryonic stem cell (ESC)-derived and induced pluripotent stem cell
(iPSC)-derived cardiomyocytes (CMs) have been very promising [12–15]. However, an
in vitro iPSC-derived cardiomyocyte model of cardiomyopathies and associated heart dis-
eases, whose production is scalable to a larger sample size, is essential to aid the discovery
of molecular and developmental changes that take place in cardiomyopathies and the
genes or genetic variants influencing these disease phenotypes to develop new diagnostics
and therapeutics.
In this study, we have generated well-characterized cardiomyocytes from lymphoblas-
toid cell line (LCL) reprogrammed iPSC lines of 12 participants of our San Antonio Mexican
American Family Study (SAMAFS), who belong to four sibships ranging from 2 to 4 sib-
lings per sibship. The validated iPSCs and their differentiated CMs were analyzed using
genome-wide RNA sequencing based transcriptomic and functional annotation analyses
to better understand the functional characteristics and disease modeling potential of the
generated CMs.
The existing rich bio-resource of immortalized LCL repositories generated from a
wide array of patients in genetic and epidemiological studies worldwide, many of them
with extensive genotypic, genomic, and phenotypic data already existing, provides a great
opportunity to reprogram iPSCs from any of these LCL donors in the context of their
own genetic identity for disease modeling and disease gene identification in cardiomy-
opathies [16–18].
2. Results
2.1. Differentiation and Lineage-Specific Functional Characteristics of Generated CMs
The CM differentiation of validated iPSC lines, reprogrammed using LCLs of 12 SAMAFS
participants and the method described in our previous publications [17,18] and detailed in
Figure S1, was induced using the Gibco PSC Cardiomyocyte Differentiation Kit (Thermo
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Fisher Scientific, Waltham, MA, USA), and the method is summarized in the schematic
presented in Figure 1A. The differentiation kit consists of a set of serum-free and xeno-free
media that enable efficient differentiation of human iPSCs to spontaneously contracting
functional cardiomyocytes. On day 14 of the differentiation, spontaneously contract-
ing CMs were characterized by immunocytochemistry (ICC) analysis of cardiac meso-
derm marker NKX2-5, mature cardiomyocyte marker TNNT2, and by genome-wide RNA
sequencing-based gene expression analysis. The CMs differentiated from all 12 sam-
ples expressed the cardiomyocyte markers NKX2-5 and TNNT2 (Figure 1B and Figure
S2). Based on the criteria normalized read count (NRC) ≥ 20 in all 12 CM samples, a
total of 12,280 genes were found expressed. The average correlation coefficient at 95%
CI between 12 CM samples, calculated based on all expressed genes, was 0.92 ± 0.02,
suggesting a uniform differentiation of generated CMs across 12 samples (Figure 1C).
The expressions of the well-known CMs genes/markers MYH6, MYL4, MYL3, MYL7,
NPPA, NPPB, MYH7, NKX2-5, TBX5, TNNT2, ACTN2, TNNC1 and MB were significantly
up-regulated across all 12 CM samples (FDR corrected p-value ≤ 0.05 and fold change
absolute (FC-abs) ≥ 2.0); whereas the expressions of pluripotency and ectodermal markers
were significantly down-regulated. The endodermal markers SOX17 and CLDN6 were
below the expression threshold of NRC ≥ 20 (Figure 1D and Table S1). The expression of
another endodermal marker CXCR4 was up-regulated (FC = 5.0) in the iPSC-generated
CMs. CXCR4 is expressed in native cardiomyocytes and plays an important role during
development and in adult tissue homeostasis [19–21].
2.2. CM Subtypes and Maturation State
Though some breakthroughs in atrial and ventricular specification of generated CMs
have been achieved [22], most currently available differentiation methods produce a het-
erogeneous population of CM subtypes, including ventricular-, atrial-, and pacemaker-like
CMs. Any heterogeneity in differentiated CM populations, which may include CM and
nonCM cells, CM subtypes, and/or maturation state across different samples, may con-
found disease modeling experiments particularly in a large, epidemiological-scale disease
gene discovery approach. Assuming that samples with a highly enriched and uniform
CM population will show significantly high correlation in the expression of CM-specific
marker genes, we performed sample correlation analysis using the quantitative expression
of 13 CMs-specific markers (Figure 2A). The average correlation coefficient at 95% CI be-
tween 12 CM samples, calculated based on the expression of 13 specific CM genes, was
0.94 ± 0.02, which suggests a uniform, highly enriched CM population across the 12 sam-
ples (Figure 2B). Second, we evaluated the concordance of CM subtypes (i.e., ventricular-,
atrial-, and sinoatrial-node-like CMs) in the differentiated CM population across the 12
samples using quantitative expression of CM subtype specific genes (Figure 2A). The
ventricle-specific gene MYL2 was below the expression threshold (NRC ≥ 20), and HEY2,
though expressed in all samples, did not change significantly between iPSCs and dif-
ferentiated CMs. The expressions of other ventricle-associated genes IRX4 and MYH7
were significantly upregulated (FC = 20.4 and 1331.1, respectively). The expressions of
atrial-specific genes (NR2F2, TBX5, NPPA, MYL7, CACNA1D, and KCNA5) and sino-atrial-
node-associated genes (TBX3, HCN4, and CACNA1G) were also significantly upregulated
(FDR corrected p-value ≤ 0.05 and fold change FC ≥ 2.0). These gene expression profiles
suggest that the majority of the CM population is of the atrial subtype (Figure 2A). To assess
the CM subtype concordance across the 12 samples, a sample correlation analysis using
these CM subtype specific genes was performed, and the average correlation coefficient at
95% CI between the 12 CM samples was 0.89 ± 0.04, suggesting concordant CM subtypes
across these samples (Figure 2C). Thirdly, the maturation state of the generated CMs across
the 12 samples was assessed using quantitative expression of genes associated with bio-
logical processes involved in CM maturation, that is (1) myofibril maturation marked by
isoform switching of several sarcomere components such as MYH6 to MYH7, TNNI1 to
TNNI3, MYL7 to MYL2, and TTN-N2BA to TTN-N2B; (2) changes in the expression of ion
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channel handling genes (KCNJ2, HCN4, CACNA1C, RYR2, and ATP2A2); (3) changes in the
genes involved in cellular metabolism (HOOK1, PKM, PPARGC1A, PPARA, and ESRRA);
and (4) changes in the cell cycle and cell adhesion associated genes (CDK1, CCNB1, AURKB,
CDH2, DSG2, DSC2, JUP, PKP2, DSP, and GJA1). A sample correlation analysis using these
CM maturity-associated genes (correlation coefficient at 95% CI 0.95 ± 0.02) suggest a
uniform CM maturation state across the 12 samples (Figure 2A,D).
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Figure 1. Characterization of induced pluripotent stem cell (iPSC)-generated cardiomyocytes (CMs) by ICC and gene
expression analysis. (A) Schematic diagram outlining the protocol of iPSC to CM differentiation. (B) A representative ICC
image panel of iPSC-generated CMs showing expression of the CM markers NKX2-5 and TNNT2. (C) Correlation coefficient
(r2) plot based on the 12,280 genes found expressed (NRC ≥ 20) in 12 iPSC-generated CMs. (D) Gene expression plot
showing average differential expression of cardiomyocytes, pluripotency, ectodermal, and endodermal markers between
12 iPSCs and their generated 12 CM lines.
2.3. Differentially Expressed (DE) Genes
To identify the unique transcriptomic signature of the generated CMs and the mecha-
nistic gene expression changes that occurred during the differentiation of validated iPSCs
into CMs, we performed a genome-wide differential gene expression analysis between the
12 iPSCs and their differentiated CMs.
A total of 271 and 167 million mRNA 50bp single-end reads were obtained for 12 iPSC
lines and their differentiated CMs, respectively.
The 13,460 genes having an NRC ≥ 20.0 in all 12 iPSC and/or 12 CM samples were
considered expressed and included in the differential gene expression analysis. Following
the criteria moderated t statistics FDR-corrected p-value ≤ 0.05 and FC-abs ≥ 2.0, 4191
genes were found significantly DE between iPSCs and their differentiated CMs (Table S1)
and accounted for nearly 29% of the CM’s and 28% of the iPSC’s expressed transcriptome
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(Figure 3A,B). About 79% of the observed variance in DE genes can be attributed to the
iPSC-to-CM cellular transition (Figure 3C).
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CM population across 12 CM samples. (A) Heat map showing normalized (log2) expression of CM-specific, CM-subtype-
specific, and CM maturity-associated genes in 12 iPSC-generated CM lines. (B–D) Correlation coefficient (r2) plots based 
on (B) CM-specific, (C) CM-subtype-specific, and (D) CM maturity-associated genes in 12 iPSC-generated CM lines, re-
spectively. 
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Figure 2. Expression analysis of CM-specific, CM-subtype-specific, and CM maturity-associated genes to assess uniform CM
population across 12 CM samples. (A) Heat map showing normalized (log2) expression of CM-specific, CM-subtype-specific,
and CM maturity-associated genes in 12 iPSC-generated CM lines. (B–D) Correlation coefficient (r2) plots based on (B)
CM-specific, (C) CM-subtype-specific, and (D) CM maturity-associated genes in 12 iPSC-generated CM lines, respectively.
2.4. Functional Annotation Analysis of DE Genes
A total of 2075 DE genes were significantly down regulated in differentiated CMs
a d included stemness, pluripotency and self-renewal associated tra scription factors
(POU5F1, NANOG, SOX2, FOXD3, ZFP42, and NR6A1), si naling molecules (GABRB3,
GAL, GRB7, IFITM1, KIT, SFRP2, and TDGF1), and other human iPSC/ESC-specific genes
(CD9, DIAPH2, DNMT3B, LIN28A, PODXL, TERT, ESRG, and GJA1). The functional
annotation analysis performed using the Ingenuity Pathway Analysis (IPA) platform
(QIAGEN Digital I sig ts, Redwood ity, CA, USA) showed significantly high enrichm nt
of the 2075 down-r gulated gen s in cell eath and survival (685 mRNAs; FDR-adjusted
p-value ange: 6.74 × 10−23–3.35 × 10−7), c ll cycle (355 mRNAs; FDR-adjusted p-value
ra ge: 8.94 × 10−20–3.71 × 10−7), cellular assembly and o ganization (391 mRNAs; FDR-
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adjusted p-value range: 8.94 × 10−20–3.76 × 10−7), and DNA replication, recombination,
and repair (278 mRNAs; FDR-adjusted p-value range: 8.94 × 10−20–3.96 × 10−7) cellular
functions. The downstream effects analysis as implemented in IPA predicted significant
deactivation (activation z-score ≤ −2.0) of cellular functions and processes associated with
iPSC/ESC self-renewal (Table S2).




Figure 3. Genome-wide differential gene expression analysis of 12 iPSCs and their differentiated 
12 CM lines. (A) Heat map of differentially expressed (DE) genes between 12 iPSCs and their 12 
differentiated CM lines. (B) Pie graph showing average DE vs. total expressed transcriptome in 12 
iPSCs and their differentiated CM lines. (C) Principal component analysis (PCA) of genes found 
DE between 12 iPSCs and their 12 differentiated CM lines. 
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(CD9, DIAPH2, DNMT3B, LIN28A, PODXL, TERT, ESRG, and GJA1). The functional an-
notation analysis performed using the Ingenuity Pathway Analysis (IPA) platform (QI-
AGEN Digital Insights, Redwood City, CA, USA) showed significantly high enrichment 
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Figure 3. Genom -wid differential gen expressio analysis of 12 iPSCs and their differentiated 12 CM lines. (A) Heat map
of differentially expressed (DE) genes between 12 iPSCs and their 12 differentiated CM lines. (B) Pie graph showing average
DE vs. total expressed transcriptome in 12 iPSCs and their differentiated CM lines. (C) Principal component analysis (PCA)
of genes found DE between 12 iPSCs and their 12 differentiated CM lines.
A total of 2116 DE genes were significantly upregulated in differentiated CMs. Using
IPA, these genes showed significantly high enrichment in cardiovascular system develop-
ment and fu ctions (571 mRNAs; FDR-adjusted p-value range: 1.75 × 10−66–1.61 × 10−14),
and IPA predicted significant activation of the functions associated with development
of the human heart and cardiovascular system (Table S3). Additionally, we performed
enrichment analysis of the upregulated g nes into gene ontology (GO) biological processes.
The top 10 significantly enriched GO biological processes are presented in Table 1, and
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results further validate the developmental and functional profiles of generated CMs as
determined in the IPA analysis.
Table 1. Top 10 significantly enriched gene ontology biological processes in significantly upregulated
CMs transcriptome.
GO Biological Process Overlap p-Value Adjusted p-Value
Heart development (GO:0007507) 66/149 4.09 × 10−26 2.09 × 10−22
Extracellular matrix organization
(GO:0030198) 75/229 6.62 × 10
−20 1.69 × 10−16
Cardiac muscle tissue
morphogenesis (GO:0055008) 27/36 1.43 × 10
−19 2.43 × 10−16
Circulatory system development
(GO:0072359) 48/109 3.09 × 10
−19 3.94 × 10−16
Ventricular cardiac muscle tissue
morphogenesis (GO:0055010) 24/34 1.56 × 10
−16 1.60 × 10−13
Muscle contraction (GO:0006936) 49/137 3.45 × 10−15 2.94 × 10−12
Myofibril assembly (GO:0030239) 26/47 5.10 × 10−14 3.72 × 10−11
Cardiac ventricle morphogenesis
(GO:0003208) 24/43 3.69 × 10
−13 2.35 × 10−10
Regulation of heart contraction
(GO:0008016) 36/95 2.15 × 10
−12 1.22 × 10−9
cardiac atrium morphogenesis
(GO:0003209) 11/17 1.22 × 10
−7 1.27 × 10−5
Note: The gene ontology (GO) biological process annotation 2018 was used in the enrichment analysis.
For more detailed characterization and to elucidate the disease modeling potential of
iPSC-generated CMs, we performed enrichment analysis of the 2116 genes upregulated
in CMs into several cell-type-specific and disease-specific gene sets as implemented in
Enrichr, a gene list enrichment analysis web tool [23,24].
The enrichment analysis of the CM-upregulated genes in the specific tissue/cell
type gene sets presented in Table 2 shows significant enrichment of our iPSC-generated
cardiomyocyte-upregulated genes in the primary cardiomyocytes and primary human
heart tissue gene sets.
Table 2. Top 5 significantly enriched human gene atlas cell types and GTEx tissue samples in
significantly upregulated CMs transcriptome.
Human Tissue/Cell Types Overlap p-Value Adjusted p-Value
Human Gene Atlas (up-regulated genes in human tissues from BioGPS)
Uterus 94/405 5.11 × 10−13 2.15 × 10−11
Placenta 58/201 1.17 × 10−13 9.85 × 10−12
Heart 88/415 1.23 × 10−10 3.43 × 10−9
Smooth Muscle 78/363 7.28 × 10−10 1.53 × 10−8
Cardiac Myocytes 62/273 4.36 × 10−9 7.33 × 10−8
GTEx Tissue Samples (up-regulated genes)
GTEX-X4EP-0326-SM-3P5Z6
heart female 60–69 years 210/755 1.37 × 10
−41 4.00 × 10−38
GTEX-X62O-0826-SM-46MW8
heart male 50–59 years 208/766 1.79 × 10
−39 2.62 × 10−36
GTEX-SE5C-0626-SM-2XCDV
heart female 40–49 years 229/906 4.75 × 10
−38 4.62 × 10−35
GTEX-S3XE-0426-SM-3K2AC
heart male 50–59 years 163/547 2.78 × 10
−36 2.03 × 10−33
GTEX-WY7C-1126-SM-3NB3A
heart male 50–59 years 176/637 1.88 × 10
−34 1.09 × 10−31
Note: Enrichment analysis into human gene atlas and Genotype-Tissue Expression (GTEx) project tissue sample
gene sets were performed in Enrichr [23,24], and gene sets were accessed on November 2020.
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The upregulated CM genes also showed significant enrichment in ClinVar (2019)
gene sets for human cardiomyopathies. The top five highly enriched gene sets are listed
in Table 3 and show that the iPSC-generated CMs have the potential for in vitro model-
ing of human cardiomyopathies including COVID-19-induced cytopathic effects on the
human heart.
Table 3. Top 5 significantly enriched ClinVar (2019) and one COVID-19-related gene set in significantly
upregulated CMs transcriptome.
Diseases Overlap p-Value Adjusted p-Value
ClinVar (2019) Gene Sets
Cardiomyopathy 33/48 1.13 × 10−21 2.06 × 10−19
Primary dilated
cardiomyopathy 23/34 2.94 × 10




18/22 1.24 × 10−14 7.54 × 10−13
Familial dilated
cardiomyopathy 21/30 1.66 × 10
−14 7.53 × 10−13
Myofibrillar
myopathy 5/6 7.22 × 10
−5 2.19 × 10−3





143/499 6.53 × 10−30 1.34 × 10−27
Notes: (1) ClinVar 2019 disease gene set was used in this enrichment analysis. (2) Only one SARS-CoV-2
(COVID-19)-related cardiomyocytes gene set was available at the time of this analysis.
2.5. Modeling the Effect of Major Adverse Cardiac Event (MACE) in Familial Sample
As indicated in the introduction section, the 12 SAMAFS participants whose iPSC
lines were used to differentiate CMs belonged to 4 sibships of size 4, 3, 3, and 2 siblings,
respectively, and 1 participant in the sibship of 4 reported MACE. Considering that the 2116
significantly up-regulated genes are the most functionally relevant gene set of the generated
CMs, we performed differential gene expression of the CM-upregulated genes between the
sibship with one MACE-affected sibling (n = 4) and the three unaffected sibships (n = 8). A
total of 179 genes were found to be significantly DE (moderated t statistics p-value ≤ 0.05
and FC-abs ≥ 2.0) between the affected and unaffected sibships (Table S4). The disease and
function annotation analysis of the 179 DE genes in IPA showed significant enrichment and
predicted activation of cardiovascular disease associated conditions. Arrhythmia, aortic
atherosclerosis, and dysfunction of heart were predicted to be significantly (activation
z-score ≥ 2.0) activated. Blood clot, abnormality of ventricle, valvulopathy, thrombus, and
fibrosis of myocardium were predicted to be nominally (2.0 > activation z-score ≥ 0.9)
activated (Figure 4A,B). To validate our IPA enrichment analysis results, we performed
enrichment analysis of the 179 DE genes in GO biological processes (2018) and Jensen dis-
eases, a disease gene association database mined from the literature [25]. The top 10 highly
enriched GO biological processes presented in Figure 4C included processes involved in
the development of heart and vascular tissue, negative regulation of peptidase activity,
and fibrinolysis. The top five enriched diseases included cerebrovascular disease, coronary
artery disease, congenital afibrinogenemia, atrial fibrillation, and hypertension (Figure 4D).
These results suggest that coexistence of atrial fibrillation/arrhythmia, prothrombotic and
atherosclerosis risk may be causal to or associated with MACE in the affected participant,
and the other three members of the sibship may have a higher risk of heart disease and/or
MACE. These results also show that our iPSC-generated CMs are a relevant cell model for
investigating cardiovascular disease and cardiomyopathies.
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3. Discussion
The in vitro generation of CMs by differentiating human ESCs and iPSCs provides
opportunities for in vitro modeling of cardiomyopathies and associated cardiac diseases
for disease gene discovery. Several challenges such as protocols for derivation of highly
enriched differentiated CM populations, derivation of CMs that are specific to heart cham-
bers, and maturation of generated CMs have been the focus of many studies and review
articles [22,26–30]. While overcoming these challenges is essential in achieving critical
properties of electrical excitability, electrical connectivity, calcium handling, and motor
protein functions in generated CMs for regenerative medicine and some aspects of drug
discovery and disease gene validation strategies, for a large, epidemiological-scale disease
gene discovery approach, it is critical that the production of iPSC-differentiated CMs is
scalable to a larger sample size and that the generated CMs are comparable in enrichment,
CM subtypes, and maturation properties across samples. In this study, we have shown
robust differentiation of well-characterized CMs (Figure 1) in a monolayer culture using
iPSCs generated from cryopreserved LCLs of 12 participants of our SAMAFS and a com-
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mercially available Gibco PSC Cardiomyocyte Differentiation Kit (Thermo Fisher Scientific,
Waltham, MA, USA). We performed genome-wide transcriptomic analysis to evaluate the
differentiated CM characteristics across 12 samples and the disease modeling potential.
3.1. Characterization and Disease Modeling Potential of Generated CMs
The generated CMs showed very high concordance across the 12 samples in the CM’s
total expressed transcriptome (average correlation coefficient at 95% CI = 0.92 ± 0.02) as
well as showing a gene expression profile (Figure 1D) very similar to previously published
gene expression profiles of highly enriched, iPSC-differentiated CMs [31–33]. The CMs-
upregulated transcriptome (the 2116 genes significantly upregulated in CMs) and expressed
transcriptome (the 12,280 genes having NRC ≥ 20 in all 12 CM samples) showed ~25% and
~65% overlap with upregulated genes in GTEx human heart tissue samples, respectively.
Additionally, the CMs-upregulated transcriptome and expressed transcriptome showed
22.7% and 68.9% overlap with the Cardiac-Myocyte upregulated gene set from the BioGPS
Human Gene Atlas [34]. These results and the enrichment analysis of the CMs-upregulated
transcriptome into GO biological processes and human gene atlas and GTEx tissue samples
upregulated gene sets presented in Tables 1 and 2 suggest that our iPSC-generated CMs
have a gene expression profile similar to primary human heart tissue and cardiomyocytes.
Enrichment analysis of the CM-upregulated transcriptome in GO biological pro-
cesses shows significant enrichment and ~70% and ~65% gene overlap with ventricular
cardiac muscle tissue morphogenesis (GO:0055010) and cardiac atrium morphogenesis
(GO:0003209) biological processes, respectively (Table 1). Therefore, to evaluate the heart
chamber specific characteristics of the generated CMs across 12 samples, we followed a
chamber-specific marker approach, the ventricle specific gene MYL2 was expressed be-
low the expression threshold (NRC ≥ 20) in the majority of our samples. Lee et al. [22]
have shown that induction of retinoic acid (RA) signaling in the early stages of iPSC-to-
cardiomyocyte differentiation significantly down-regulated MYL2 expression and pro-
moted atrial fate specification of iPSC-differentiated CMs. A switch from MYL7 to MYL2
has also been shown to be associated with maturation of ventricular CMs. MYL7 is ex-
pressed in all early fetal CMs and switches to MYL2 as ventricular CMs mature and the
MYL7 expression becomes restricted to atrial cardiomyocytes [30,35,36]. MYL7 was highly
expressed in all 12 samples and was significantly upregulated during CMs differentiation
(Table S1). The expression of ventricle-specific transcription factor HEY2 did not change sig-
nificantly between iPSCs and differentiated CMs and was moderately expressed (average
NRC = 181.02) in all 12 samples. HEY2 expression plays an important role in ventricular,
especially left ventricular, development by suppressing atrial identity [28,37–39]. However,
contrary to the previously reported reduced expression of IRX4 and MYH7 in RA-treated
CMs [22], the expressions of these ventricle-associated genes were significantly upregulated
(FC = 20.4 and 1331.1, respectively) in our iPSC-generated CMs, which may warrant further
investigation. The expression of atrial-specific transcription factor HEY1, which plays an
important role in the precise formation of the heart’s atrioventricular boundary [40–42],
was significantly upregulated in iPSC-differentiated CMs (FC = 16.9), and its expression
was about 2-fold higher (average NRC = 362) than that of HEY2. The expression levels
of other atrial-specific genes (NR2F2, TBX5, NPPA, MYL7, CACNA1D, and KCNA5) and
sino-atrial node associated genes (TBX3, HCN4, and CACNA1G) were also significantly
upregulated (Table S1) [22,27,28].
Human ESC/iPSC-derived CMs exhibit immature phenotypes that resemble fetal
cardiomyocytes, and despite tremendous progress in maturation methods, complete mat-
uration of the ESC/iPSC-derived CMs is yet to be achieved [30,43–48]. However, for an
epidemiological-scale disease gene discovery approach, obtaining primary cardiomyocytes
from patients and healthy controls is nearly impossible; therefore, iPSC-derived CMs whose
maturation state across samples are uniform/comparable holds tremendous potential as
the closest surrogate of primary cardiomyocytes. As detailed in the results, we assessed
the maturation state of our iPSC-generated CMs across 12 samples using quantitative
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expression of genes involved in CM maturation processes such as myofibril maturation,
expression of ion channel handling genes, changes in the expression of genes involved in
cellular metabolism, and changes in the expression of cell cycle and cell adhesion associ-
ated genes (Figure 2A). The sarcomeric isoforms of both mature and immature myofibrils
marked by MYH6, MYH7, TNNI1, TNNI3, and MYL7 were expressed and significantly
upregulated in our iPSC-differentiated CMs; however, MYL2 expression was below the
expression threshold or borderline expressed in most samples. As indicated above, MYL7
is predominantly expressed in fetal, as well as mature, atrial cardiomyocytes, and MYL2
expression is restricted to mature ventricular cardiomyocytes [30]. It is also important to
note that expression of all mature myofibril isoforms was lower than the immature myofib-
ril isoforms (Figure 2A). The automaticity ion channel gene HCN4 and calcium handling
molecules CACNA1C, RYR2, and ATP2A2 [30,49,50] were upregulated and moderately
expressed in all 12 CM samples. However, the expression of mature ventricular ion channel
KCNJ2 was below the expression threshold or borderline expressed in most samples. The
metabolic maturation of CMs involves activation of metabolic transcriptional regulators,
upregulation of fatty acid metabolism, oxidative phosphorylation, and mitochondrial bio-
genesis genes, and downregulation of glycolytic genes [51–53]. The expression of metabolic
transcriptional regulators PPARGC1A and PPARA were significantly upregulated in our
iPSC-differentiated CMs. The metabolic transcriptional regulators NRF1 and ESRRA,
though expressed in all samples, did not change significantly in iPSCs and their differ-
entiated CMs. Hexokinase, which executes the first step of glycolysis, is predominantly
isoform HK1 in immature (fetal and neonatal) CMs, and isoform HK2, which exhibits less
glycolytic activity, is predominantly expressed in mature CMs. Both HK1 and HK2 were
highly expressed in our iPSC-differentiated CMs (Figure 2A). However, HK1 expression
was nominally higher than HK2 (FC = 1.5). Cardiomyocyte proliferation rate declines
rapidly postnatally and upon maturation of the iPSC-differentiated CMs [30]. The cell cycle
regulators CDK1, CCNB1, and AURKB, which promote G2/M phase progression during the
cell cycle [54], were significantly down-regulated in our iPSC-differentiated CMs (Table S1).
The co-overexpression of CDK1-CCNB1 and CDK4-CCND complexes that are involved
in G2/M phase and G1/S phase progressions, respectively, were sufficient to reactivate
proliferation in mature, cell division ceased CMs [55]. The expressions of CDK4, CCNDs,
and other activators of CM proliferation, the ERBB2 and YAP1, did not change significantly
between iPSCs and their differentiated CMs. Specialized cardiomyocyte–cardiomyocyte
junctions, the intercalated discs (ICDs) are involved in maturational integration of CMs into
cardiac tissue. Immature CMs lack ICDs, and ICD components are either not expressed,
localized to the interior of cells, or are throughout the cell surface. ICDs are hybrid junc-
tions and comprise three major types of cell adhesions: fascia adherens, desmosomes, and
gap junctions [56,57]. The fascia adherens protein gene CDH2; desmosomes-associated
genes DSG2, DSC2, JUP, PKP2, and DSP; and gap junction protein gene GJA1 were all
significantly upregulated in our iPSC-differentiated CMs (Figure 2A).
Overall, our iPSC-differentiated CMs have a transcriptomic and functional profile of
immature atrial-like CMs. The correlation analysis based on CM-specific, CM-subtype-
specific, and CM maturity-associated genes, however, suggests a highly concordant CM
population across our 12 samples (Figure 2B–D).
Having comprehensively evaluated the transcriptomic and functional characteristics
of our iPSC-differentiated CMs across 12 samples, we next explored the cardiomyopathies
and associated heart disease modeling potential of the iPSC-generated CMs. The enrich-
ment analysis of the CM upregulated transcriptome (2116 genes) in the ClinVar-2019 gene
sets [58] showed significant enrichment of cardiomyopathies and associated disease. Nearly
70% to 80% of genes listed as associated with cardiomyopathies and associated disease
in the ClinVar 2019 data set were significantly upregulated in our iPSC-differentiated
CMs (Table 3). Furthermore, the CM-upregulated transcriptome also showed significantly
high enrichment in a gene set (GSE150392) down-regulated by SARS-CoV-2 infection in
cardiomyocytes. These results strongly suggest that our iPSC-generated CMs, that are
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highly concordant in their transcriptomic and functional characteristics across multiple
samples, are a relevant cell model to study cardiomyopathy and associated heart disease.
Furthermore, additional maturation and subtype-specific characterization of the generated
CMs including the electrophysiological characterization may be performed on a small
sample to validate the findings of a larger, epidemiological-scale disease gene discovery
study or to model a well-characterized disease-specific phenotype.
3.2. MACE-Associated Transcriptomic Changes in Familial CM Samples
As detailed in the results, differential gene expression analysis of the CM-upregulated
transcriptome (2116 genes) identified 179 genes that were significantly DE (moderated t
statistics p-value ≤ 0.05 and FC-abs ≥ 2.0) between the MACE-affected and unaffected
sibships. The disease and function annotation analysis of the 179 DE genes in IPA identified
significant enrichment and predicted activation of arrhythmia (p-value = 1.19 × 10−8; acti-
vation z-score = 2.4). Furthermore, atrial fibrillation was also found significantly enriched
using IPA as well as Jensen diseases data set (p-values = 1.06 × 10−5 and 5.53 × 10−5,
respectively) [25]. An upstream regulator analysis of the 179 DE genes in IPA identified
significant down-regulation of PITX2 gene (FC = −2.6) in the MACE-affected sibship and
dysregulated expression of its downstream targets (54 genes significantly DE between the
MACE-affected and unaffected sibships), and several of them were enriched in arrhythmia
(Figure 4A). The PITX2-associated variability including over- and under- expression were
reported in atrial fibrillation patients, and a dose-dependent regulatory role of PITX2 in
normal atrial function has been suggested [59–61]. The causal role of PITX2 variation in
atrial fibrillation and overall arrhythmogenesis involves multiple regulatory pathways [62].
The PITX2 forms an incoherent regulatory circuit with TBX5 (significantly downregulated
in the MACE-affected sibship; FC = −2.7); both regulate each other’s expression and also
regulate the expression of their downstream targets antagonistically, and perturbation of
this co-regulated network increases atrial fibrillation susceptibility [63–65]. The expressions
of PITX2 and TBX5 downstream targets, the delayed rectifier potassium channel gene
KCNA5, and the low-voltage-activated calcium channel gene CACNA1G were significantly
downregulated in the MACE-affected sibship (FC = −3.0 and −3.2, respectively). The loss-
of-function mutations and reduced expression of these ion channel genes were reported in
atrial fibrillation patients [66–71]. The PITX2 also antagonistically regulates TBX3 expres-
sion [72,73], which was significantly upregulated (FC = 4.5) in the MACE-affected sibship.
TBX3, another member of the T-box transcription factors, regulates the sino-atrial-node
gene program, and its upregulated expression causes sino-atrial remodeling of mature
atrial and ventricular cardiomyocytes including remodeling of the contractile apparatus,
which is poorly developed in sino-atrial/pacemaker cells [74–76]. The expression of one of
its components, the TNNI3, which is also a marker for CM maturation, was significantly
downregulated (FC = 3.7) in the MACE-affected sibship. The expression of Z-discs and
intercalated discs associated DES was also significantly down regulated in the MACE-
affected sibship (Table S4). The down regulated expressions of PITX2 and TBX5, and
associated sino-atrial and fetal-like remodeling of cardiomyocytes, may also be involved in
dysregulation of DE genes enriched in “abnormality of heart ventricle” and “dysfunction
of heart”, for example, significant down-regulation of HAND1 and HAND2 (FC = −2.3 and
−2.2, respectively) in the MACE-affected sibship. The expressions of HAND1 and HAND2
play a role, which is poorly understood, in left and right ventricle development and overall
cardio morphogenesis [77,78]. The “blood clot” and “thrombus” formation were also
significantly enriched and nominally activated (p-value = 8.05 × 10−8 and 2.99 × 10−7,
respectively; activation z-score = 1.9 and 1.1, respectively) in the 179 DE genes, suggesting
activation of coagulation and prothrombotic intrinsic program in CMs generated from
the MACE-affected sibship. Aortic atherosclerosis was also predicted to be significantly
activated (activation z-score = 2.2) in the MACE-affected sibship. There is contradictory
evidence that atrial fibrillation and arrhythmia-induced remodeling of CMs may activate
the blood coagulation and prothrombotic intrinsic program in atrial CMs [79–83]. The
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other arrhythmia-associated risk factors such as “fibrosis of myocardium” and “hyperten-
sion” were also significantly enriched (p-value = 4.06 × 10−5 and 6.14 × 10−5, respectively)
in 179 genes found DE between the MACE-affected and unaffected sibships. Further-
more, the expression of AGT was significantly upregulated (FC = 3.6) in CMs generated
from the MACE-affected sibship samples. The upregulated expression of AGT is a risk
factor for several of the disease conditions enriched in the MACE-associated DE genes
(Figure 4). The enrichment of genes found DE between MACE-affected sibship CMs and
MACE-unaffected sibship CMs in atrial fibrillation/arrhythmia and prothrombotic and
atherosclerosis disease conditions (Figure 4) correlates with risk favoring adverse car-
diac events in the MACE-affected sibship [84,85]. Overall, our results show that human
iPSC-derived CM cellular/gene expression phenotypes likely exist that correlate with
genetic risk of MACE. This new finding supports larger epidemiological-scale studies of
iPSC-generated CMs to identify quantitative cellular phenotypes that better index disease
risk.
4. Materials and Methods
The 12 validated iPSC lines used in this study were previously reprogrammed from
cryopreserved lymphoblastoid cells lines (LCLs) of our San Antonio Mexican American
Family Study (SAMAFS) participants and following the methodology described in our
previous publications [17,18].
4.1. CMs Differentiation
The differentiation of validated iPSC lines (Figure S1) into spontaneously contracting
CMs was performed using the commercially available Gibco PSC Cardiomyocyte Differen-
tiation Kit (Thermo Fisher Scientific, Waltham, MA, USA), and methods are summarized
in the schematic presented in Figure 1A. Briefly, well-characterized and validated iPSCs
cultured in feeder-free conditions until 70% to 80% confluent were harvested using Gibco
StemPro Accutase and then seeded on GeltrexTM (both from Thermo Fisher Scientific,
Waltham, MA, USA) coated tissue culture plates at a density of ~4 × 104 cells/cm2 in
mTeSR-1 medium (Stem Cell Technologies Inc., Cambridge, MA, USA) supplemented
with 10 µM ROCK inhibitor Y27632 (ATCC, Manassas, VA, USA). The mTeSR-1 medium
was changed daily for the following two days or until the culture reached 50% to 70%
confluency. On day 4, when iPSC cultures were 50% to 70% confluent, the medium was
switched to Gibco Cardiomyocytes Differentiation Medium A. On day 6, the medium was
replaced with Gibco Cardiomyocytes Differentiation Medium B, and from day 8 onwards,
the differentiating cells were maintained in Gibco Cardiomyocyte Maintenance Medium
until day 14, and the medium was changed every other day (the Gibco Cardiomyocytes
Differentiation Medium A, Medium B, and the Gibco Cardiomyocyte Maintenance Medium
were all part of the Gibco PSC Cardiomyocyte Differentiation Kit). On day 14, the 12 iPSC-
differentiated, spontaneously contracting CM lines were harvested for characterization
and total RNA extraction.
4.2. Characterization of Generated CMs
Each generated CM line was characterized by two complementary methods: (1) the
ICC analysis of cardiac mesoderm marker NKX2-5 and mature cardiomyocyte marker
TNNT2; and (2) the genome-wide mRNA sequencing-based gene expression analysis of
the cardiomyocyte-specific genes/markers as detailed in Figure 1D and Figure S2.
For ICC characterization, each iPSC-differentiated CM line was fixed using 4% paraformalde-
hyde (MilliporeSigma, St. Louis, MO, USA) and then immunoassayed using commercially
available primary antibodies against cardiac mesoderm marker NKX2-5 and cardiomyocyte
marker TNNT2 (both from Thermo Fisher Scientific, Waltham, MA, USA) and standard ICC
techniques. In each assay, cells were counterstained with 4’,6-diamidino-2-phenylindole
dihydrochloride (DAPI) nuclear stain (MilliporeSigma, St. Louis, MO, USA) and were im-
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aged on a Carl Zeiss epifluorescence equipped inverted microscope (Carl Zeiss Microscopy,
LLC, White Plains, NY, USA).
4.3. RNA Extraction and Sequencing
Total RNA extraction: The total RNA was extracted from snap-frozen cell pellets
(~3–5 × 106 cells) of 12 well-characterized, validated iPSC lines and their differentiated
CM lines using the commercially available RNeasy Mini Kit (Qiagen, Germantown, MD,
USA) and the manufacturer’s protocol. RNA quality and quantity were assessed using a
NanoDrop 2000 Spectrophotometer (Thermo Fisher Scientific, Waltham, MA, USA) and an
Agilent 2200 TapeStation system (Agilent, Santa Clara, CA, USA).
mRNA Sequencing: The mRNA sequencing libraries were prepared using 1µg total
RNA per sample (extracted from 12 iPSC and 12 CM lines) and the Illumina TruSeq
RNA sample preparation kit v2 (Illumina, Inc., San Diego, CA, USA). Briefly, the poly-A
tail containing mRNA molecules was enriched from total RNA using oligo dT attached
magnetic beads. The mRNA-enriched samples were then fragmented into ∼200–600 base
pair sizes using divalent cations and elevated temperature. The first-strand cDNA was
synthesized from resulting cleaved RNA fragments and using reverse transcriptase, and
random primers, followed by second-strand cDNA synthesis, using DNA polymerase-I
and RNase H. The synthesized cDNA fragments were end-repaired, and adaptor ligations
were performed. The end-repaired and adaptor ligated cDNA libraries were purified and
enriched by PCR and then deep-sequenced on an Illumina HiSeq 2500 platform.
Sequence Analysis: Raw fastq sequence files were generated and demultiplexed using
Illumina bcl2fastq software (Illumina, Inc., San Diego, CA, USA). After pre-alignment QCs,
sequences were aligned to human genome assembly GRCh38 (hg38) and mapped to RefSeq
transcripts using StrandNGS software v3.4 (Strand Life Sciences Pvt. Ltd., Bangalore,
India). The aligned reads were filtered based on default read quality metrics, and log
transformation and “DESeq” normalization were applied. The known mRNAs having
NRC ≥ 20 in 12 iPSC and/or their differentiated CM lines were considered expressed
and selected for differential gene expression analysis. For CMs, expressed transcriptome
genes/mRNAs having NRC ≥ 20 in all 12 CM lines were counted expressed.
4.4. Differential Gene Expression Analyses
To identify genes/mRNAs that were DE between iPSCs and their differentiated CMs
and between MACE-affected and unaffected sibships, moderated t statistics and expression
fold change analyses were performed. The significance criteria for each differential gene
expression analysis are detailed in the results.
4.5. Disease and Function Annotation Analyses
Disease and functional annotations and upstream regulator analyses were performed
on significantly DE genes/mRNAs identified between iPSCs and their differentiated CMs,
and between MACE-affected and unaffected sibships using the IPA platform (QIAGEN
Digital Insights, Redwood City, CA, USA) and Enrichr, a gene list enrichment analysis web
tool [23,24]. In IPA, right-tailed Fisher’s exact test p-values corrected for FDR were used to
calculate enrichment significance, and the direction of functional change was assessed by
the activation z-score detailed in [86]. In Enrichr, enrichment significance was computed
using three approaches detailed in Chen et al. [23]. The first one is the Fisher exact test,
and we have ranked our Enrichr results presented in Table 1, Table 2, and Table 3 based
on Fisher exact test p-values. We have also presented in Table 1, Table 2, and Table 3 the
adjusted enrichment p-values computed in Enrichr by combining the three approaches
detailed in [23,24].
5. Conclusions
In conclusion, we have demonstrated robust differentiation of spontaneously con-
tracting CMs across multiple iPSC lines reprogrammed from cryopreserved LCLs. Our
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comprehensive transcriptomic analysis of the generated CM lines identified 4191 genes
that were significantly DE between iPSCs and their differentiated CMs. The enrichment
analysis of the CMs significantly upregulated transcriptome (2116 genes) in primary cell
and tissue-specific gene sets shows that the generated CMs express CM-specific genes,
and the upregulated transcriptome was significantly overlapped and enriched in primary
cardiomyocytes and primary heart tissue upregulated genes. The transcriptomic analysis
of the CM subtypes and maturation state shows that our iPSC-generated CMs possess a
transcriptomic and functional profile of immature atrial-like CMs. However, the gener-
ated CM population across 12 samples was highly concordant, and disease and function
enrichment analysis shows that the generated CMs are a relevant cell model to study car-
diomyopathies and associated heart diseases. Furthermore, modeling the effect of MACE
in our generated CM familial samples identified gene expression phenotypes consistent
with the predisposition of the MACE-affected sibship to arrhythmia, prothrombotic, and
atherosclerosis risk. It is important to note that MACE status was assigned after a subject
suffered a clinically diagnosed adverse cardiac event in our longitudinal study.
Overall, our data and methodology provide a proof of the principle that iPSC-derived
CMs, whose production is scalable to a large sample size for an epidemiological-scale
disease gene discovery approach while maintaining uniform/comparable CM subpopu-
lations and maturation states across samples, hold a tremendous potential as the closest
surrogate of primary cardiomyocytes. Furthermore, our study shows that human iPSC-
generated CMs express phenotypic variation that is correlated with genetic risk of MACE.
The potential existence of novel cellular biomarkers supports larger studies of human
iPSC-derived CMs. Such non-invasive cell-specific biomarkers may lead to improvements
in the prediction of risk (even in children) and point to potential causal genes involved in
disease risk.
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